US FDA rejects broader arthritis use of Janssen Biotech's Simponi
This article was originally published in Scrip
The US FDA rejected Janssen Biotech's supplemental biologics license application to expand the use of its antitumor necrosis factor (TNF) alpha Simponi (golimumab) as a treatment for inhibiting the progression of structural damage, inducing major clinical response and maintenance of reduction of signs and symptoms and maintenance of improved physical function in patients with moderately to severely active rheumatoid arthritis.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.